Mass Spectrometry-based Proteomics and Glycoproteomics in COVID-19 Biomarkers Identification:A Mini-review  

作　　者：Li Zhong Lin Zhu Zong-Wei Cai 

机构地区：[1]State Key Laboratory of Environmental and Biological Analysis,Department of Chemistry,Hong Kong Baptist University,224 Waterloo Road,Kowloon Tong,Hong Kong SAR,China

出　　处：《Journal of Analysis and Testing》2021年第4期298-313,共16页分析检测（英文）

基　　金：funded by SZSTC(SGDX20190816230207535);obtained a donation from Kwok Chung Bo Fun Charitable Fund,which commemorates the establishment of the Kwok Yat Wai Endowed Chair of Environmental and Biological Analysis。

摘　　要：The first corona-pandemic,coronavirus disease 2019(COVID-19)caused a huge health crisis and incalculable damage worldwide.Knowledge of how to cure the disease is urgently needed.Emerging immune escaping mutants of the virus suggested that it may be potentially persistent in human society as a regular health threat as the flu virus.Therefore,it is imperative to identify appropriate biomarkers to indicate pathological and physiological states,and more importantly,clinic outcomes.Proteins are the performers of life functions,and their abundance and modification status can directly reflect the immune status.Protein glycosylation serves a great impact in modulating protein function.The use of both unmodified and glycosylated proteins as biomarkers has also been proved feasible in the studies of SARS,Zika virus,influenza,etc.In recent years,mass spectrometry-based glycoproteomics,as well as proteomics approaches,advanced significantly due to the evolution of mass spectrometry.We focus on the current development of the mass spectrometry-based strategy for COVID-19 biomarkers’investigation.Potential application of glycoproteomics approaches and challenges in biomarkers identification are also discussed.

关 键 词：COVID-19 SARS-CoV-2 BIOMARKER PROTEOMICS GLYCOPROTEOMICS 

分 类 号：R563.1[医药卫生—呼吸系统] O657.63[医药卫生—内科学]